Perivascular Immune Cells in Coronary Homeostasis: Mechanisms, Clinical Relevance, and Therapeutic Implications

Abstract

Perivascular immune cells play an essential role in maintaining coronary homeostasis by modulating vascular inflammation, endothelial function, and tissue repair. Recent advances in immunology and cardiovascular research have highlighted the complex interplay between perivascular immune compartments and the coronary vasculature, elucidating their critical involvement in both physiological and pathological processes. This review synthesizes current evidence regarding the cellular mechanisms, clinical significance, and therapeutic opportunities related to perivascular immune cells in coronary homeostasis, providing a comprehensive overview for clinicians and researchers.

Introduction

The coronary vasculature is not only a conduit for blood supply but also a dynamic immunological interface where various immune cells orchestrate vascular health and disease. Perivascular immune cells, comprising populations such as macrophages, dendritic cells, mast cells, and lymphocytes, reside within the adventitia and periarterial tissue, forming a specialized niche that regulates coronary homeostasis. Understanding the roles of these immune cells is increasingly recognized as vital in the context of ischemic heart disease, atherosclerosis, and vascular remodeling. This article explores the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, and therapeutic perspectives related to perivascular immune cells in the maintenance of coronary health.

Epidemiology / Disease Burden

Coronary artery disease (CAD) remains the leading cause of morbidity and mortality globally. While traditional cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and smoking are well established, emerging evidence implicates immune dysregulation as a key contributor to the burden of disease. Studies suggest that chronic low-grade inflammation, orchestrated in part by perivascular immune cells, is ubiquitous in patients with subclinical and overt coronary pathology. The prevalence of immune cell infiltration and activation in coronary arteries is particularly high in individuals with metabolic syndrome, autoimmune diseases, and chronic infections, underlining the epidemiological significance of immunovascular interactions in CAD.

Pathophysiology

Perivascular immune cells contribute to coronary homeostasis through complex mechanisms involving immune surveillance, inflammation modulation, and tissue repair. Macrophages in the adventitia can sense endothelial injury and secrete cytokines that influence smooth muscle cell behavior, while dendritic cells bridge innate and adaptive immunity by presenting antigens to T cells. Mast cells, through the release of vasoactive mediators such as histamine and tryptase, regulate vascular permeability and tone. In healthy states, these cells support vessel integrity and repair; however, chronic activation leads to pathological remodeling, endothelial dysfunction, and atherogenesis. Recent research has elucidated the role of perivascular tertiary lymphoid structures, which serve as local immune hubs that can perpetuate inflammation and promote plaque instability in coronary arteries.

Risk Factors

Several risk factors predispose individuals to maladaptive perivascular immune responses. Traditional cardiovascular risk factors, such as hypercholesterolemia and hypertension, are associated with increased perivascular infiltration of pro-inflammatory macrophages and T cells. Autoimmune disorders, including systemic lupus erythematosus and rheumatoid arthritis, are characterized by aberrant immune cell trafficking to the coronary adventitia. Environmental factors, such as chronic infection and exposure to air pollution, can also prime perivascular immune cells for heightened inflammatory responses, accelerating vascular injury and atherosclerosis.

Clinical Features

The clinical manifestations of perivascular immune cell dysfunction are diverse and range from subclinical endothelial dysfunction to overt acute coronary syndromes. Patients may present with stable angina, progressive exertional symptoms, or acute chest pain if immune-driven inflammation destabilizes coronary plaques. Biomarkers of immune activation, such as high-sensitivity C-reactive protein (hs-CRP) and circulating cytokines, often correlate with disease activity and risk stratification. Importantly, the presence of perivascular inflammation may also influence vascular reactivity, contributing to vasospastic angina in susceptible individuals.

Diagnosis

Diagnosing perivascular immune cell involvement in coronary pathology requires a multimodal approach. Non-invasive imaging techniques, such as positron emission tomography (PET) with radiolabeled tracers targeting immune cells or inflammation (e.g., 18F-FDG PET), provide insight into vascular inflammation and perivascular immune activity. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) may reveal structural changes in the vessel wall consistent with immune-mediated remodeling. Endomyocardial biopsy and immunohistochemistry remain the gold standard for identifying specific immune cell populations within the coronary adventitia but are reserved for select clinical scenarios due to their invasiveness.

Treatment & Management

Management of coronary disease with significant perivascular immune involvement extends beyond conventional risk factor modification and anti-platelet therapy. Statins, in addition to their lipid-lowering properties, exhibit immunomodulatory effects that reduce perivascular inflammation and macrophage activation. Emerging evidence supports the role of anti-inflammatory agents, such as colchicine and interleukin-1β inhibitors (e.g., canakinumab), in reducing recurrent cardiovascular events by targeting immune pathways. Immunosuppressive therapy may be indicated in autoimmune-mediated coronary vasculitis, tailored to the underlying etiology and immune cell profile. Lifestyle interventions, including dietary modification and smoking cessation, remain foundational by mitigating systemic inflammation and immune activation.

Recent Advances / Emerging Therapies

Recent advances have expanded therapeutic options for modulating perivascular immunity in coronary disease. Monoclonal antibodies targeting specific immune mediators, such as PCSK9 inhibitors, not only lower cholesterol but also attenuate vascular inflammation. Trials investigating the inhibition of T cell co-stimulatory pathways and the use of regulatory T cell infusions show promise in restoring vascular immune tolerance. Nanoparticle-based drug delivery systems offer the potential for targeted modulation of perivascular immune cells, minimizing systemic side effects. Genomic and transcriptomic profiling of perivascular immune cells is shedding light on patient-specific pathways amenable to precision immunotherapy.

Guideline Recommendations

Current international guidelines emphasize aggressive risk factor modification for the prevention of coronary artery disease. The 2021 European Society of Cardiology (ESC) guidelines recommend considering anti-inflammatory therapy in patients with recurrent events despite optimal conventional therapy. The American Heart Association (AHA) highlights the importance of inflammation in atherosclerosis and supports ongoing research into immunomodulatory strategies. There is growing consensus for the integration of immune profiling into cardiovascular risk assessment, particularly in high-risk and autoimmune populations, to personalize therapy and improve outcomes.

Conclusion

Perivascular immune cells are central to the maintenance of coronary homeostasis, serving as both protectors and potential perpetrators of vascular injury depending on the immunological milieu. Advances in diagnostic imaging, biomarker discovery, and immunotherapeutic interventions are rapidly transforming the landscape of coronary artery disease management. Continued research into the mechanisms underpinning perivascular immune cell function will foster the development of targeted therapies, with the promise of improved cardiovascular outcomes for diverse patient populations.